Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + Chemotherapy in HER2+ Digestive System Cancers
NCT03185988Phase 2Unknown
- Start
- Jul 2017
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in Esophageal Squamous Cell Carcinoma (ESCC), biliary tract cancer (BTC), colorectal cancer (CRC), gastrointestinal carcinoma. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)biliary tract cancer (BTC)colorectal cancer (CRC)gastrointestinal carcinoma
Beyond the preview
Go deeper on NCT03185988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185988.